AG
BMRN icon

Advisor Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advisor Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$808K Buy
9,565
+446
+5% +$33.7K 0.01% 1346
2019
Q3 		$614K Buy
9,119
+1,885
+26% +$145K ﹤0.01% 1462
2019
Q2 		$619K Buy
7,234
+565
+8% +$48.3K ﹤0.01% 1464
2019
Q1 		$592K Buy
6,669
+551
+9% +$51.1K ﹤0.01% 1468
2018
Q4 		$521K Buy
6,118
+1,128
+23% +$107K 0.01% 1374
2018
Q3 		$483K Buy
4,990
+1,520
+44% +$152K ﹤0.01% 1498
2018
Q2 		$327K Buy
3,470
+1,680
+94% +$147K ﹤0.01% 1628
2018
Q1 		$145K Sell
1,790
-660
-27% -$56.6K ﹤0.01% 2235
2017
Q4 		$219K Sell
2,450
-97
-4% -$8.43K ﹤0.01% 1919
2017
Q3 		$237K Sell
2,547
-185
-7% -$16.3K ﹤0.01% 1726
2017
Q2 		$247K Sell
2,732
-361
-12% -$32.8K ﹤0.01% 1628
2017
Q1 		$270K Sell
3,093
-488
-14% -$43.4K 0.01% 1452
2016
Q4 		$298K Buy
3,581
+309
+9% +$26.6K 0.01% 1306
2016
Q3 		$304K Buy
3,272
+1,247
+62% +$117K 0.01% 1263
2016
Q2 		$155K Buy
+2,025
New +$172K ﹤0.01% 1628

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Advisor Group's BMRN Position: Q4 2019 in Review

Advisor Group increased its BioMarin Pharmaceuticals (BMRN) stake by 4.9% in Q4 2019, buying an estimated $33.7K and bringing the position to 9,565 shares worth $808K. The position accounts for 0.01% of the portfolio, ranked #1346.

Advisor Group first reported a position in BMRN in Q2 2016 and has held it in 15 quarters since. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Advisor Group held 9,565 shares of BioMarin Pharmaceuticals worth $808K as of Q4 2019.
  • Advisor Group bought 446 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $33.7K.
  • BioMarin Pharmaceuticals made up 0.01% of Advisor Group's portfolio in Q4 2019, its #1346 holding.
  • Advisor Group first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.